Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 9/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.54 |
| ▸ | AHCY | P23526 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | PI4KA | P42356 | 3/20 | 0.50 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.50 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.50 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.48 |
| ▸ | NSD2 | O96028 | 1/20 | 0.45 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL384146 | 1.00 | ADORA2A (0.54) | ADORA2AADORA1AHCYALDH1A1PI4KA | |
| SCHEMBL99603 | 0.87 | AHCY (0.64) | ADORA2AADORA1AHCYALDH1A1PI4KA | |
| SCHEMBL6363452 | 0.87 | AHCY (0.64) | ADORA2AADORA1AHCYALDH1A1PI4KA | |
| SCHEMBL3860366 | 0.84 | CCNE1 (0.51) | ADORA2AADORA1AHCY | |
| SCHEMBL8620522 | 0.84 | CCNE1 (0.51) | ADORA2AADORA1AHCY | |
| SCHEMBL9189761 | 0.82 | ADORA2A (0.55) | ADORA2AADORA1AHCYALDH1A1PI4KA | |
| SCHEMBL384145 | 0.82 | CYP3A4 (0.72) | ADORA2AADORA1AHCYALDH1A1CYP3A4 | |
| SCHEMBL9190527 | 0.82 | CYP3A4 (0.72) | ADORA2AADORA1AHCYALDH1A1CYP3A4 | |
| SCHEMBL2928584 | 0.82 | CYP3A4 (0.72) | ADORA2AADORA1AHCYALDH1A1CYP3A4 | |
| SCHEMBL608687 | 0.82 | CYP3A4 (0.68) | ADORA2AADORA1AHCYALDH1A1PI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PHARMACIA CORPORATION | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PTGS2, PTGS1, PTGES2 | ADORA2A 690/4885ADORA1 1331/4885AHCY 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.